ArticleBMC pregnancy and childbirth2025
FSP1 and CoQ10 have the potential to serve as biomarkers for severe preeclampsia.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The relationship between trace element imbalance, oxidative stress, and endothelial dysfunction in preeclampsia diagnosis.BMC pregnancy and childbirth · 2026Article
- Dual role of ferroptosis in embryonic development, cascade amplification regulatory mechanism and targeted intervention.Frontiers in cell and developmental biology · 2026Review
- The role of oxidative stress and antioxidant approaches in preeclampsia: A narrative review.European journal of midwifery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere preeclampsia is a condition that poses a threat to pregnant women and fetuses, which requires prompt treatment and intervention. The ferroapoptosis suppressor protein 1(FSP1)-ubiquinone10 (CoQ10)-nicotinamide adenine dinucleotide phosphate(NADPH) pathway, a recently identified pathway that inhibits ferroptosis, is parallel to the cystine/glutathione (GSH) /GPX4 pathway. However, its expression in pregnant women with severe preeclampsia has not yet been investigated.
methodsA total of 198 pregnant women were enrolled in the baseline characterization study, and we measure the levels of chemicals, proteins, and mRNAs associated with the FSP1/CoQ10/NADPH pathway in the placenta, umbilical arterial blood, and maternal blood of pregnant women with severe preeclampsia and normal pregnant women.
resultsThe results indicate that severe preeclampsia has more serious adverse pregnancy outcomes, and ferroptosis does occur in its placenta. In addition, FSP1 and CoQ10 showed a downward trend in the placenta of pregnant women with severe preeclampsia, and the utilization rate of NADPH was also reduced. This study also found that the expression levels of FSP1 and CoQ10 were downregulated in both maternal blood and umbilical artery blood.
conclusionsBased on observations. results of this study, we suggest that FSP1 and CoQ10 can be used in the future as new biomarkers for monitoring the progression of severe preeclampsia, and that they may become new targets for the treatment of severe preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.